Trials / Withdrawn
WithdrawnNCT05067946
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
A Phase 2/3, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GX-19N, A DNA Vaccine, in Healthy Individuals Who Have Received One of the COVID-19 Vaccines
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GX-19N | DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen |
| OTHER | Placebo | GX-19N formulation buffer |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-10-01
- Completion
- 2023-10-01
- First posted
- 2021-10-05
- Last updated
- 2022-04-12
Source: ClinicalTrials.gov record NCT05067946. Inclusion in this directory is not an endorsement.